Antitumor power of oncolytic HSV engineered with IL-12 and IL-15.

Mol Ther Oncol · 2025 · PMC12357093 · PMID 40821720

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

did not reach statistical significancep > 0.05actually significant

While the difference in percentage increase between the RG2002 and HSV-1/WT groups did not reach statistical significance ( p > 0.05), the OVs expressing IL-12 and IL-15 exhibited a substantial increase relative to the other treatment groups ( p < 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.